InterCure Ltd. (INCR)
USD 1.35
(-1.83%)
USD 1.35
(-1.83%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -61.95 Million ILS | -238.24% |
| 2022 | 44.81 Million ILS | 514.3% |
| 2021 | 7.29 Million ILS | 120.24% |
| 2020 | -36.04 Million ILS | -1102.94% |
| 2019 | -2.99 Million ILS | 76.59% |
| 2018 | -12.79 Million ILS | -143.37% |
| 2017 | -5.25 Million ILS | -2081.27% |
| 2016 | 265.41 Thousand ILS | 114.14% |
| 2015 | -1.87 Million ILS | 50.49% |
| 2014 | -3.79 Million ILS | 42.59% |
| 2013 | -6.6 Million ILS | -115.21% |
| 2012 | 43.44 Million ILS | 738.72% |
| 2011 | -6.8 Million ILS | 45.86% |
| 2010 | -12.56 Million ILS | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 716.5 Thousand ILS | 102.14% |
| 2024 Q2 | 716.5 Thousand ILS | 0.0% |
| 2023 Q1 | 92 Thousand ILS | -98.25% |
| 2023 Q2 | 4.88 Million ILS | 5207.61% |
| 2023 Q4 | -33.52 Million ILS | 0.0% |
| 2023 Q3 | -33.52 Million ILS | -786.63% |
| 2023 FY | -61.95 Million ILS | -238.24% |
| 2022 Q3 | 7.25 Million ILS | -53.6% |
| 2022 Q2 | 15.63 Million ILS | 16.93% |
| 2022 Q1 | 13.37 Million ILS | 535.78% |
| 2022 FY | 44.81 Million ILS | 514.3% |
| 2022 Q4 | 5.26 Million ILS | -27.43% |
| 2021 Q1 | 3.21 Million ILS | -65.16% |
| 2021 FY | 7.29 Million ILS | 120.24% |
| 2021 Q4 | -3.06 Million ILS | -86.68% |
| 2021 Q2 | 6.19 Million ILS | 92.72% |
| 2021 Q3 | -1.64 Million ILS | -126.55% |
| 2020 Q3 | 1.73 Million ILS | 277.3% |
| 2020 FY | -36.04 Million ILS | -1102.94% |
| 2020 Q1 | -47.2 Million ILS | -243.46% |
| 2020 Q2 | -978 Thousand ILS | 97.93% |
| 2020 Q4 | 9.22 Million ILS | 431.83% |
| 2019 Q3 | -15.5 Million ILS | -34.38% |
| 2019 FY | -2.99 Million ILS | 76.59% |
| 2019 Q1 | 37.79 Million ILS | 1047.77% |
| 2019 Q2 | -11.54 Million ILS | -130.53% |
| 2019 Q4 | -13.74 Million ILS | 11.37% |
| 2018 FY | -12.79 Million ILS | -143.37% |
| 2018 Q4 | -3.98 Million ILS | 0.0% |
| 2018 Q3 | -3.98 Million ILS | -65.41% |
| 2018 Q2 | -2.41 Million ILS | 0.0% |
| 2018 Q1 | -2.41 Million ILS | -56.36% |
| 2017 Q4 | -1.54 Million ILS | 0.0% |
| 2017 Q3 | -1.54 Million ILS | -28.13% |
| 2017 Q1 | -1.24 Million ILS | -512.85% |
| 2017 Q2 | -1.2 Million ILS | 3.69% |
| 2017 FY | -5.25 Million ILS | -2081.27% |
| 2016 Q2 | -902.28 Thousand ILS | -177.74% |
| 2016 Q1 | 1.16 Million ILS | 229.63% |
| 2016 FY | 265.41 Thousand ILS | 114.14% |
| 2016 Q4 | -203.89 Thousand ILS | -204.44% |
| 2016 Q3 | 195.23 Thousand ILS | 121.64% |
| 2015 FY | -1.87 Million ILS | 50.49% |
| 2015 Q3 | -903.69 Thousand ILS | -631.31% |
| 2015 Q2 | 170.08 Thousand ILS | 166.13% |
| 2015 Q1 | -257.19 Thousand ILS | 58.72% |
| 2015 Q4 | -895.38 Thousand ILS | 0.92% |
| 2014 Q3 | -1.43 Million ILS | -32.09% |
| 2014 Q2 | -1.08 Million ILS | -103.11% |
| 2014 Q1 | -535.77 Thousand ILS | 65.36% |
| 2014 FY | -3.79 Million ILS | 42.59% |
| 2014 Q4 | -623.11 Thousand ILS | 56.65% |
| 2013 Q4 | -1.54 Million ILS | 32.05% |
| 2013 FY | -6.6 Million ILS | -115.21% |
| 2013 Q3 | -2.27 Million ILS | -48.57% |
| 2013 Q2 | -1.53 Million ILS | -16.49% |
| 2013 Q1 | -1.31 Million ILS | 65.52% |
| 2012 Q1 | -3.32 Million ILS | -95.32% |
| 2012 Q2 | -371.74 Thousand ILS | 88.81% |
| 2012 Q3 | 51.15 Million ILS | 13859.91% |
| 2012 Q4 | -3.81 Million ILS | -107.46% |
| 2012 FY | 43.44 Million ILS | 738.72% |
| 2011 FY | -6.8 Million ILS | 45.86% |
| 2011 Q3 | -1.7 Million ILS | 0.0% |
| 2011 Q1 | -1.7 Million ILS | 45.86% |
| 2011 Q2 | -1.7 Million ILS | 0.0% |
| 2011 Q4 | -1.7 Million ILS | 0.0% |
| 2010 Q4 | -3.14 Million ILS | 0.0% |
| 2010 Q1 | -3.14 Million ILS | 0.0% |
| 2010 Q3 | -3.14 Million ILS | 0.0% |
| 2010 FY | -12.56 Million ILS | 0.0% |
| 2010 Q2 | -3.14 Million ILS | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Journey Medical Corporation | -3.85 Million USD | -1508.072% |
| Safety Shot Inc | -15.08 Million USD | -310.786% |
| Bright Green Corporation | -13.12 Million USD | -371.973% |
| Alvotech | -551.73 Million USD | 88.77% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -687.281% |
| Cosmos Health Inc. | -18.54 Million USD | -234.143% |
| Dynavax Technologies Corporation | -6.38 Million USD | -869.776% |
| Embecta Corp. | 70.4 Million USD | 188.01% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 70.39% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 55.64% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 247.68% |
| PainReform Ltd. | -9.34 Million USD | -563.089% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -1275.02% |
| SCYNEXIS, Inc. | 67.04 Million USD | 192.42% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -1899.624% |
| Alpha Teknova, Inc. | -36.78 Million USD | -68.458% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 429.938% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 228.666% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -1275.02% |
| Procaps Group, S.A. | 42.54 Million USD | 245.649% |
| Theratechnologies Inc. | -23.95 Million USD | -158.626% |
| Harrow Health, Inc. | -24.41 Million USD | -153.816% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -1181.468% |
| Biofrontera Inc. | -20.13 Million USD | -207.779% |
| DURECT Corporation | -27.62 Million USD | -124.294% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 4808.131% |
| Cronos Group Inc. | -73.96 Million USD | 16.23% |
| OptiNose, Inc. | -35.48 Million USD | -74.616% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 93.818% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -46.826% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 359.069% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 1352.963% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 39306.368% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -886.715% |
| Radius Health, Inc. | -25.79 Million USD | -140.235% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -905.328% |
| ProPhase Labs, Inc. | -16.78 Million USD | -269.199% |
| Phibro Animal Health Corporation | 2.41 Million USD | 2664.528% |
| Procaps Group S.A. | 42.54 Million USD | 245.649% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -502.831% |
| Viatris Inc. | 54.7 Million USD | 213.271% |
| Rockwell Medical, Inc. | -8.43 Million USD | -634.198% |
| Aytu BioPharma, Inc. | -15.84 Million USD | -291.057% |
| SIGA Technologies, Inc. | 68.06 Million USD | 191.024% |
| Tilray Brands, Inc. | -244.98 Million USD | 74.709% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 615.766% |
| Shineco, Inc. | -22.44 Million USD | -175.999% |
| PetIQ, Inc. | 2.13 Million USD | 3007.508% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -1340.292% |
| Incannex Healthcare Limited | -18.45 Million USD | -235.657% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 124.813% |
| Alimera Sciences, Inc. | -20.13 Million USD | -207.764% |
| Silver Spike Investment Corp. | 7.34 Million USD | 944.116% |
| Assertio Holdings, Inc. | -331.94 Million USD | 81.334% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -839.809% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -659.005% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | -246.159% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -208.91% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 61.342% |
| Hempacco Co., Inc. | -13.12 Million USD | -372.03% |
| Talphera, Inc. | -18.39 Million USD | -236.789% |
| Alvotech | -551.73 Million USD | 88.77% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 273.837% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 118.967% |
| Currenc Group, Inc. | -15.3 Million USD | -304.787% |
| Kamada Ltd. | 8.28 Million USD | 847.936% |
| Indivior PLC | 2 Million USD | 3197.95% |
| Evoke Pharma, Inc. | -7.79 Million USD | -695.132% |
| Flora Growth Corp. | -57.03 Million USD | -8.631% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -208.91% |
| Evolus, Inc. | -61.68 Million USD | -0.444% |
| HUTCHMED (China) Limited | 100.78 Million USD | 161.479% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 145.046% |
| Akanda Corp. | -32.27 Million USD | -91.972% |